Published in Antiviral Res on April 03, 2015
Genome-editing Technologies for Gene and Cell Therapy. Mol Ther (2016) 1.41
Applications of CRISPR technologies in research and beyond. Nat Biotechnol (2016) 1.34
Chronic hepatitis B: A wave of new therapies on the horizon. Antiviral Res (2015) 0.99
Metabolism and function of hepatitis B virus cccDNA: Implications for the development of cccDNA-targeting antiviral therapeutics. Antiviral Res (2015) 0.94
Genome editing and the next generation of antiviral therapy. Hum Genet (2016) 0.88
CRISPR/Cas9 and cancer targets: future possibilities and present challenges. Oncotarget (2016) 0.81
Progress With Developing Use of Gene Editing To Cure Chronic Infection With Hepatitis B Virus. Mol Ther (2016) 0.80
A combinational CRISPR/Cas9 gene-editing approach can halt HIV replication and prevent viral escape. Sci Rep (2017) 0.80
Progress and Prospects of Anti-HBV Gene Therapy Development. Int J Mol Sci (2015) 0.80
Harnessing the Prokaryotic Adaptive Immune System as a Eukaryotic Antiviral Defense. Trends Microbiol (2016) 0.79
New horizon for radical cure of chronic hepatitis B virus infection. World J Hepatol (2016) 0.79
An Effective Molecular Target Site in Hepatitis B Virus S Gene for Cas9 Cleavage and Mutational Inactivation. Int J Biol Sci (2016) 0.77
Application of CRISPR/Cas9 Technology to HBV. Int J Mol Sci (2015) 0.76
Gene Editing Approaches against Viral Infections and Strategy to Prevent Occurrence of Viral Escape. PLoS Pathog (2016) 0.75
A CRISPR toolbox to study virus-host interactions. Nat Rev Microbiol (2017) 0.75
Removal of Integrated Hepatitis B Virus DNA Using CRISPR-Cas9. Front Cell Infect Microbiol (2017) 0.75
A non-viral CRISPR/Cas9 delivery system for therapeutic gene targeting in vivo. Cell Res (2017) 0.75
Future Therapy for Hepatitis B Virus: Role of Immunomodulators. Curr Hepatol Rep (2016) 0.75
CRISPR-Cas9: a promising tool for gene editing on induced pluripotent stem cells. Korean J Intern Med (2017) 0.75
Inhibition of JCPyV infection mediated by targeted viral genome editing using CRISPR/Cas9. Sci Rep (2016) 0.75
Treatment of hepatitis B virus: an update. Future Microbiol (2016) 0.75
Drugs in Development for Hepatitis B. Drugs (2017) 0.75
Glucose-regulated protein 78 is an antiviral against hepatitis A virus replication. Exp Ther Med (2017) 0.75
ssAAVs containing cassettes encoding SaCas9 and guides targeting hepatitis B virus inactivate replication of the virus in cultured cells. Sci Rep (2017) 0.75